Efficacy and Safety of Immunosuppressive Therapy for PBC–AIH Overlap Syndrome Accompanied by Decompensated Cirrhosis: A Real-World Study

Table 1

Demographic and clinical features, laboratory parameters, prognostic scores, and decompensation characteristics between the two groups.

Variables	UDCA-only group (N=14)	UDCA+IS group (N=14)	P value
Age at entry (years)	60.0 (51.3, 61.3)	48.0 (42.5, 53.5)	0.024
Gender (F/M)	13/1	12/2	>0.999
TBIL, μmol/L	29.0 (23.2, 41.1)	38.9 (35.2, 127.1)	0.035
ALT, IU/L	66.5 (44.8, 127.0)	112.0 (45.7, 174.5)	0.401
AST, IU/L	103.5 (78.5, 129.8)	170.0 (91.0, 212.5)	0.401
ALP, IU/L	349.5 (257.8, 519.0)	294.0 (196.5, 430.5)	0.285
GGT, IU/L	268.5 (157.0, 656.3)	229.5 (51.8, 293.5)	0.285
ALB, g/L	37.6 (31.8, 39.9)	32.3 (29.9, 35.5)	0.031
GLB, g/L	43.4 (37.4, 47.1)	45.4 (35.3, 50.2)	0.511
INR	1.1 (1.0, 1.2)	1.1 (1.0, 1.2)	0.734
Cr, μmol/L	57.3 (51.8, 66.3)	53.5 (43.3, 61.3)	0.137
ANA positive, N (%)	13/14	12/14	>0.999
AMA positive, N (%)	9/14	9/14	>0.999
LKM positive, N (%)	0	0	-
LC-1 positive, N (%)	0	0	-
SLA positive, N (%)	0	0	-
Concurrent autoimmune diseases, N (%)	4/14	6 /14	0.695
IgG (g/L)	22.8 (20.2, 25.7)	28.6 (19.7, 32.4)	0.125
IgM (g/L)	2.2 (1.3, 5.7)	2.7 (2.4, 3.0)	0.306
APRI score	3.9 (2.2, 5.3)	6.4 (3.9, 7.2)	0.051
FIB-4 index	6.6 (4.9, 8.7)	11.7 (6.7, 18.9)	0.075
Complications
Ascites	12/14	10/14	0.648
Variceal bleeding	2/14	4/14	0.648
Prognostic scores
Child-Pugh score	6.5 (6.0, 7.0)	8.0 (6.0, 8.0)	0.265

Note. UDCA, ursodeoxycholic acid; IS, immunosuppressants; TBIL, total bilirubin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase; GGT, gamma-glutamyl transpeptidase; ALB, albumin; GLB, globulin; ANA, antinuclear antibody; AMA, anti-mitochondrial antibody; LKM, liver–kidney microsomal antibody; LC-1, antibody against liver cytosol type 1 antigen; SLA, soluble liver antigen/liver pancreas antibody; APRI, aspartate aminotransferase to platelet ratio index; FIB-4, fibrosis 4 index.